FHIR IG analytics

Resources that use this resource

No resources found

Resources that this resource uses

No resources found

Narrative

Note: links and images are rebased to the (stated) source

Source1

{
  "resourceType": "Composition",
  "id": "399871",
  "meta": {
    "versionId": "5",
    "lastUpdated": "2025-12-11T20:35:21.032Z",
    "profile": [
      "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-report"
    ]
  },
  "language": "en",
  "text": {
    "status": "generated",
    "div": "<!-- snip (see above) -->"
  },
  "contained": [
    {
      "resourceType": "Group",
      "id": "FG000",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/exposure-group"
        ]
      },
      "name": "NCT03421379 Flow Group Glucagon Nasal Powder/Glucagon Hydrochloride",
      "description": "A single dose of 3 milligram (mg) glucagon nasal powder was administered intranasally in period 1 then 1 mg single dose intramuscular glucagon hydrochloride solution was administered in period 2.",
      "type": "person",
      "membership": "enumerated",
      "characteristic": [
        {
          "code": {
            "text": "Research Study from which this is a flow group"
          },
          "valueReference": {
            "display": "NCT03421379"
          },
          "exclude": false
        }
      ]
    },
    {
      "resourceType": "Group",
      "id": "FG001",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/exposure-group"
        ]
      },
      "name": "NCT03421379 Flow Group Glucagon Hydrochloride Solution/Glucagon Nasal Powder",
      "description": "A single dose of 1 mg glucagon hydrochloride solution was administered intramuscular (IM) in period 1 then 3 mg single dose glucagon nasal powder was administered in period 2.",
      "type": "person",
      "membership": "enumerated",
      "characteristic": [
        {
          "code": {
            "text": "Research Study from which this is a flow group"
          },
          "valueReference": {
            "display": "NCT03421379"
          },
          "exclude": false
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-flow-milestone-0-Period-1-group-FG000",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
        ]
      },
      "identifier": [
        {
          "type": {
            "text": "FEvIR Linking Identifier"
          },
          "system": "https://fevir.net/FLI",
          "value": "NCT03421379-flow-milestone-0-Period-1-group-FG000",
          "assigner": {
            "display": "Computable Publishing LLC"
          }
        }
      ],
      "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Period 1",
      "status": "active",
      "author": [
        {
          "name": "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
        }
      ],
      "useContext": [
        {
          "code": {
            "system": "https://fevir.net/resources/CodeSystem/179423",
            "code": "evidence-communication",
            "display": "Evidence Communication"
          },
          "valueCodeableConcept": {
            "coding": [
              {
                "system": "https://fevir.net/resources/CodeSystem/179423",
                "code": "ParticipantFlowEvidence",
                "display": "ParticipantFlowEvidence"
              }
            ]
          }
        }
      ],
      "variableDefinition": [
        {
          "variableRole": "population",
          "observed": {
            "reference": "#FG000",
            "type": "Group",
            "display": "Glucagon Nasal Powder/Glucagon Hydrochloride"
          }
        },
        {
          "variableRole": "outcome",
          "observed": {
            "display": "STARTED at Period 1"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "coding": [
              {
                "system": "https://fevir.net/sevco",
                "code": "STATO:0000047",
                "display": "Count"
              }
            ]
          },
          "quantity": {
            "value": 34
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-flow-milestone-0-Period-1-group-FG001",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
        ]
      },
      "identifier": [
        {
          "type": {
            "text": "FEvIR Linking Identifier"
          },
          "system": "https://fevir.net/FLI",
          "value": "NCT03421379-flow-milestone-0-Period-1-group-FG001",
          "assigner": {
            "display": "Computable Publishing LLC"
          }
        }
      ],
      "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Period 1",
      "status": "active",
      "author": [
        {
          "name": "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
        }
      ],
      "useContext": [
        {
          "code": {
            "system": "https://fevir.net/resources/CodeSystem/179423",
            "code": "evidence-communication",
            "display": "Evidence Communication"
          },
          "valueCodeableConcept": {
            "coding": [
              {
                "system": "https://fevir.net/resources/CodeSystem/179423",
                "code": "ParticipantFlowEvidence",
                "display": "ParticipantFlowEvidence"
              }
            ]
          }
        }
      ],
      "variableDefinition": [
        {
          "variableRole": "population",
          "observed": {
            "reference": "#FG001",
            "type": "Group",
            "display": "Glucagon Hydrochloride Solution/Glucagon Nasal Powder"
          }
        },
        {
          "variableRole": "outcome",
          "observed": {
            "display": "STARTED at Period 1"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "coding": [
              {
                "system": "https://fevir.net/sevco",
                "code": "STATO:0000047",
                "display": "Count"
              }
            ]
          },
          "quantity": {
            "value": 41
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-flow-milestone-1-Period-1-group-FG000",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
        ]
      },
      "identifier": [
        {
          "type": {
            "text": "FEvIR Linking Identifier"
          },
          "system": "https://fevir.net/FLI",
          "value": "NCT03421379-flow-milestone-1-Period-1-group-FG000",
          "assigner": {
            "display": "Computable Publishing LLC"
          }
        }
      ],
      "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - Received at Least One Dose of Study Drug at Period 1",
      "status": "active",
      "author": [
        {
          "name": "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
        }
      ],
      "useContext": [
        {
          "code": {
            "system": "https://fevir.net/resources/CodeSystem/179423",
            "code": "evidence-communication",
            "display": "Evidence Communication"
          },
          "valueCodeableConcept": {
            "coding": [
              {
                "system": "https://fevir.net/resources/CodeSystem/179423",
                "code": "ParticipantFlowEvidence",
                "display": "ParticipantFlowEvidence"
              }
            ]
          }
        }
      ],
      "variableDefinition": [
        {
          "variableRole": "population",
          "observed": {
            "reference": "#FG000",
            "type": "Group",
            "display": "Glucagon Nasal Powder/Glucagon Hydrochloride"
          }
        },
        {
          "variableRole": "outcome",
          "observed": {
            "display": "Received at Least One Dose of Study Drug at Period 1"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "coding": [
              {
                "system": "https://fevir.net/sevco",
                "code": "STATO:0000047",
                "display": "Count"
              }
            ]
          },
          "quantity": {
            "value": 33
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-flow-milestone-1-Period-1-group-FG001",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
        ]
      },
      "identifier": [
        {
          "type": {
            "text": "FEvIR Linking Identifier"
          },
          "system": "https://fevir.net/FLI",
          "value": "NCT03421379-flow-milestone-1-Period-1-group-FG001",
          "assigner": {
            "display": "Computable Publishing LLC"
          }
        }
      ],
      "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - Received at Least One Dose of Study Drug at Period 1",
      "status": "active",
      "author": [
        {
          "name": "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
        }
      ],
      "useContext": [
        {
          "code": {
            "system": "https://fevir.net/resources/CodeSystem/179423",
            "code": "evidence-communication",
            "display": "Evidence Communication"
          },
          "valueCodeableConcept": {
            "coding": [
              {
                "system": "https://fevir.net/resources/CodeSystem/179423",
                "code": "ParticipantFlowEvidence",
                "display": "ParticipantFlowEvidence"
              }
            ]
          }
        }
      ],
      "variableDefinition": [
        {
          "variableRole": "population",
          "observed": {
            "reference": "#FG001",
            "type": "Group",
            "display": "Glucagon Hydrochloride Solution/Glucagon Nasal Powder"
          }
        },
        {
          "variableRole": "outcome",
          "observed": {
            "display": "Received at Least One Dose of Study Drug at Period 1"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "coding": [
              {
                "system": "https://fevir.net/sevco",
                "code": "STATO:0000047",
                "display": "Count"
              }
            ]
          },
          "quantity": {
            "value": 39
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-flow-milestone-2-Period-1-group-FG000",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
        ]
      },
      "identifier": [
        {
          "type": {
            "text": "FEvIR Linking Identifier"
          },
          "system": "https://fevir.net/FLI",
          "value": "NCT03421379-flow-milestone-2-Period-1-group-FG000",
          "assigner": {
            "display": "Computable Publishing LLC"
          }
        }
      ],
      "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Period 1",
      "status": "active",
      "author": [
        {
          "name": "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
        }
      ],
      "useContext": [
        {
          "code": {
            "system": "https://fevir.net/resources/CodeSystem/179423",
            "code": "evidence-communication",
            "display": "Evidence Communication"
          },
          "valueCodeableConcept": {
            "coding": [
              {
                "system": "https://fevir.net/resources/CodeSystem/179423",
                "code": "ParticipantFlowEvidence",
                "display": "ParticipantFlowEvidence"
              }
            ]
          }
        }
      ],
      "variableDefinition": [
        {
          "variableRole": "population",
          "observed": {
            "reference": "#FG000",
            "type": "Group",
            "display": "Glucagon Nasal Powder/Glucagon Hydrochloride"
          }
        },
        {
          "variableRole": "outcome",
          "observed": {
            "display": "COMPLETED at Period 1"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "coding": [
              {
                "system": "https://fevir.net/sevco",
                "code": "STATO:0000047",
                "display": "Count"
              }
            ]
          },
          "quantity": {
            "value": 32
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-flow-milestone-2-Period-1-group-FG001",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
        ]
      },
      "identifier": [
        {
          "type": {
            "text": "FEvIR Linking Identifier"
          },
          "system": "https://fevir.net/FLI",
          "value": "NCT03421379-flow-milestone-2-Period-1-group-FG001",
          "assigner": {
            "display": "Computable Publishing LLC"
          }
        }
      ],
      "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Period 1",
      "status": "active",
      "author": [
        {
          "name": "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
        }
      ],
      "useContext": [
        {
          "code": {
            "system": "https://fevir.net/resources/CodeSystem/179423",
            "code": "evidence-communication",
            "display": "Evidence Communication"
          },
          "valueCodeableConcept": {
            "coding": [
              {
                "system": "https://fevir.net/resources/CodeSystem/179423",
                "code": "ParticipantFlowEvidence",
                "display": "ParticipantFlowEvidence"
              }
            ]
          }
        }
      ],
      "variableDefinition": [
        {
          "variableRole": "population",
          "observed": {
            "reference": "#FG001",
            "type": "Group",
            "display": "Glucagon Hydrochloride Solution/Glucagon Nasal Powder"
          }
        },
        {
          "variableRole": "outcome",
          "observed": {
            "display": "COMPLETED at Period 1"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "coding": [
              {
                "system": "https://fevir.net/sevco",
                "code": "STATO:0000047",
                "display": "Count"
              }
            ]
          },
          "quantity": {
            "value": 37
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-flow-milestone-3-Period-1-group-FG000",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
        ]
      },
      "identifier": [
        {
          "type": {
            "text": "FEvIR Linking Identifier"
          },
          "system": "https://fevir.net/FLI",
          "value": "NCT03421379-flow-milestone-3-Period-1-group-FG000",
          "assigner": {
            "display": "Computable Publishing LLC"
          }
        }
      ],
      "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Period 1",
      "status": "active",
      "author": [
        {
          "name": "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
        }
      ],
      "useContext": [
        {
          "code": {
            "system": "https://fevir.net/resources/CodeSystem/179423",
            "code": "evidence-communication",
            "display": "Evidence Communication"
          },
          "valueCodeableConcept": {
            "coding": [
              {
                "system": "https://fevir.net/resources/CodeSystem/179423",
                "code": "ParticipantFlowEvidence",
                "display": "ParticipantFlowEvidence"
              }
            ]
          }
        }
      ],
      "variableDefinition": [
        {
          "variableRole": "population",
          "observed": {
            "reference": "#FG000",
            "type": "Group",
            "display": "Glucagon Nasal Powder/Glucagon Hydrochloride"
          }
        },
        {
          "variableRole": "outcome",
          "observed": {
            "display": "NOT COMPLETED at Period 1"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "coding": [
              {
                "system": "https://fevir.net/sevco",
                "code": "STATO:0000047",
                "display": "Count"
              }
            ]
          },
          "quantity": {
            "value": 2
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-flow-milestone-3-Period-1-group-FG001",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
        ]
      },
      "identifier": [
        {
          "type": {
            "text": "FEvIR Linking Identifier"
          },
          "system": "https://fevir.net/FLI",
          "value": "NCT03421379-flow-milestone-3-Period-1-group-FG001",
          "assigner": {
            "display": "Computable Publishing LLC"
          }
        }
      ],
      "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Period 1",
      "status": "active",
      "author": [
        {
          "name": "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
        }
      ],
      "useContext": [
        {
          "code": {
            "system": "https://fevir.net/resources/CodeSystem/179423",
            "code": "evidence-communication",
            "display": "Evidence Communication"
          },
          "valueCodeableConcept": {
            "coding": [
              {
                "system": "https://fevir.net/resources/CodeSystem/179423",
                "code": "ParticipantFlowEvidence",
                "display": "ParticipantFlowEvidence"
              }
            ]
          }
        }
      ],
      "variableDefinition": [
        {
          "variableRole": "population",
          "observed": {
            "reference": "#FG001",
            "type": "Group",
            "display": "Glucagon Hydrochloride Solution/Glucagon Nasal Powder"
          }
        },
        {
          "variableRole": "outcome",
          "observed": {
            "display": "NOT COMPLETED at Period 1"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "coding": [
              {
                "system": "https://fevir.net/sevco",
                "code": "STATO:0000047",
                "display": "Count"
              }
            ]
          },
          "quantity": {
            "value": 4
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-flow-reason-Period-1-group-FG000",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
        ]
      },
      "identifier": [
        {
          "type": {
            "text": "FEvIR Linking Identifier"
          },
          "system": "https://fevir.net/FLI",
          "value": "NCT03421379-flow-reason-Period-1-group-FG000",
          "assigner": {
            "display": "Computable Publishing LLC"
          }
        }
      ],
      "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - Reasons for withdraw at Period 1",
      "status": "active",
      "author": [
        {
          "name": "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
        }
      ],
      "useContext": [
        {
          "code": {
            "system": "https://fevir.net/resources/CodeSystem/179423",
            "code": "evidence-communication",
            "display": "Evidence Communication"
          },
          "valueCodeableConcept": {
            "coding": [
              {
                "system": "https://fevir.net/resources/CodeSystem/179423",
                "code": "ParticipantFlowEvidence",
                "display": "ParticipantFlowEvidence"
              }
            ]
          }
        }
      ],
      "variableDefinition": [
        {
          "variableRole": "population",
          "observed": {
            "reference": "#FG000",
            "type": "Group",
            "display": "Glucagon Nasal Powder/Glucagon Hydrochloride"
          }
        },
        {
          "variableRole": "outcome",
          "observed": {
            "display": "Reasons for withdraw at Period 1"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "coding": [
              {
                "system": "https://fevir.net/sevco",
                "code": "STATO:0000047",
                "display": "Count"
              }
            ]
          },
          "category": {
            "text": "Withdrawal by Subject"
          },
          "quantity": {
            "value": 0
          }
        },
        {
          "statisticType": {
            "coding": [
              {
                "system": "https://fevir.net/sevco",
                "code": "STATO:0000047",
                "display": "Count"
              }
            ]
          },
          "category": {
            "text": "Physician Decision"
          },
          "quantity": {
            "value": 1
          }
        },
        {
          "statisticType": {
            "coding": [
              {
                "system": "https://fevir.net/sevco",
                "code": "STATO:0000047",
                "display": "Count"
              }
            ]
          },
          "category": {
            "text": "Did not receive treatment"
          },
          "quantity": {
            "value": 1
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-flow-reason-Period-1-group-FG001",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
        ]
      },
      "identifier": [
        {
          "type": {
            "text": "FEvIR Linking Identifier"
          },
          "system": "https://fevir.net/FLI",
          "value": "NCT03421379-flow-reason-Period-1-group-FG001",
          "assigner": {
            "display": "Computable Publishing LLC"
          }
        }
      ],
      "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - Reasons for withdraw at Period 1",
      "status": "active",
      "author": [
        {
          "name": "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
        }
      ],
      "useContext": [
        {
          "code": {
            "system": "https://fevir.net/resources/CodeSystem/179423",
            "code": "evidence-communication",
            "display": "Evidence Communication"
          },
          "valueCodeableConcept": {
            "coding": [
              {
                "system": "https://fevir.net/resources/CodeSystem/179423",
                "code": "ParticipantFlowEvidence",
                "display": "ParticipantFlowEvidence"
              }
            ]
          }
        }
      ],
      "variableDefinition": [
        {
          "variableRole": "population",
          "observed": {
            "reference": "#FG001",
            "type": "Group",
            "display": "Glucagon Hydrochloride Solution/Glucagon Nasal Powder"
          }
        },
        {
          "variableRole": "outcome",
          "observed": {
            "display": "Reasons for withdraw at Period 1"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "coding": [
              {
                "system": "https://fevir.net/sevco",
                "code": "STATO:0000047",
                "display": "Count"
              }
            ]
          },
          "category": {
            "text": "Withdrawal by Subject"
          },
          "quantity": {
            "value": 1
          }
        },
        {
          "statisticType": {
            "coding": [
              {
                "system": "https://fevir.net/sevco",
                "code": "STATO:0000047",
                "display": "Count"
              }
            ]
          },
          "category": {
            "text": "Physician Decision"
          },
          "quantity": {
            "value": 1
          }
        },
        {
          "statisticType": {
            "coding": [
              {
                "system": "https://fevir.net/sevco",
                "code": "STATO:0000047",
                "display": "Count"
              }
            ]
          },
          "category": {
            "text": "Did not receive treatment"
          },
          "quantity": {
            "value": 2
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG000",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
        ]
      },
      "identifier": [
        {
          "type": {
            "text": "FEvIR Linking Identifier"
          },
          "system": "https://fevir.net/FLI",
          "value": "NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG000",
          "assigner": {
            "display": "Computable Publishing LLC"
          }
        }
      ],
      "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Washout Period (3 to 14 Days)",
      "status": "active",
      "author": [
        {
          "name": "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
        }
      ],
      "useContext": [
        {
          "code": {
            "system": "https://fevir.net/resources/CodeSystem/179423",
            "code": "evidence-communication",
            "display": "Evidence Communication"
          },
          "valueCodeableConcept": {
            "coding": [
              {
                "system": "https://fevir.net/resources/CodeSystem/179423",
                "code": "ParticipantFlowEvidence",
                "display": "ParticipantFlowEvidence"
              }
            ]
          }
        }
      ],
      "variableDefinition": [
        {
          "variableRole": "population",
          "observed": {
            "reference": "#FG000",
            "type": "Group",
            "display": "Glucagon Nasal Powder/Glucagon Hydrochloride"
          }
        },
        {
          "variableRole": "outcome",
          "observed": {
            "display": "STARTED at Washout Period (3 to 14 Days)"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "coding": [
              {
                "system": "https://fevir.net/sevco",
                "code": "STATO:0000047",
                "display": "Count"
              }
            ]
          },
          "quantity": {
            "value": 32
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG001",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
        ]
      },
      "identifier": [
        {
          "type": {
            "text": "FEvIR Linking Identifier"
          },
          "system": "https://fevir.net/FLI",
          "value": "NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG001",
          "assigner": {
            "display": "Computable Publishing LLC"
          }
        }
      ],
      "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Washout Period (3 to 14 Days)",
      "status": "active",
      "author": [
        {
          "name": "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
        }
      ],
      "useContext": [
        {
          "code": {
            "system": "https://fevir.net/resources/CodeSystem/179423",
            "code": "evidence-communication",
            "display": "Evidence Communication"
          },
          "valueCodeableConcept": {
            "coding": [
              {
                "system": "https://fevir.net/resources/CodeSystem/179423",
                "code": "ParticipantFlowEvidence",
                "display": "ParticipantFlowEvidence"
              }
            ]
          }
        }
      ],
      "variableDefinition": [
        {
          "variableRole": "population",
          "observed": {
            "reference": "#FG001",
            "type": "Group",
            "display": "Glucagon Hydrochloride Solution/Glucagon Nasal Powder"
          }
        },
        {
          "variableRole": "outcome",
          "observed": {
            "display": "STARTED at Washout Period (3 to 14 Days)"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "coding": [
              {
                "system": "https://fevir.net/sevco",
                "code": "STATO:0000047",
                "display": "Count"
              }
            ]
          },
          "quantity": {
            "value": 37
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG000",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
        ]
      },
      "identifier": [
        {
          "type": {
            "text": "FEvIR Linking Identifier"
          },
          "system": "https://fevir.net/FLI",
          "value": "NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG000",
          "assigner": {
            "display": "Computable Publishing LLC"
          }
        }
      ],
      "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Washout Period (3 to 14 Days)",
      "status": "active",
      "author": [
        {
          "name": "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
        }
      ],
      "useContext": [
        {
          "code": {
            "system": "https://fevir.net/resources/CodeSystem/179423",
            "code": "evidence-communication",
            "display": "Evidence Communication"
          },
          "valueCodeableConcept": {
            "coding": [
              {
                "system": "https://fevir.net/resources/CodeSystem/179423",
                "code": "ParticipantFlowEvidence",
                "display": "ParticipantFlowEvidence"
              }
            ]
          }
        }
      ],
      "variableDefinition": [
        {
          "variableRole": "population",
          "observed": {
            "reference": "#FG000",
            "type": "Group",
            "display": "Glucagon Nasal Powder/Glucagon Hydrochloride"
          }
        },
        {
          "variableRole": "outcome",
          "observed": {
            "display": "COMPLETED at Washout Period (3 to 14 Days)"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "coding": [
              {
                "system": "https://fevir.net/sevco",
                "code": "STATO:0000047",
                "display": "Count"
              }
            ]
          },
          "quantity": {
            "value": 32
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG001",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
        ]
      },
      "identifier": [
        {
          "type": {
            "text": "FEvIR Linking Identifier"
          },
          "system": "https://fevir.net/FLI",
          "value": "NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG001",
          "assigner": {
            "display": "Computable Publishing LLC"
          }
        }
      ],
      "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Washout Period (3 to 14 Days)",
      "status": "active",
      "author": [
        {
          "name": "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
        }
      ],
      "useContext": [
        {
          "code": {
            "system": "https://fevir.net/resources/CodeSystem/179423",
            "code": "evidence-communication",
            "display": "Evidence Communication"
          },
          "valueCodeableConcept": {
            "coding": [
              {
                "system": "https://fevir.net/resources/CodeSystem/179423",
                "code": "ParticipantFlowEvidence",
                "display": "ParticipantFlowEvidence"
              }
            ]
          }
        }
      ],
      "variableDefinition": [
        {
          "variableRole": "population",
          "observed": {
            "reference": "#FG001",
            "type": "Group",
            "display": "Glucagon Hydrochloride Solution/Glucagon Nasal Powder"
          }
        },
        {
          "variableRole": "outcome",
          "observed": {
            "display": "COMPLETED at Washout Period (3 to 14 Days)"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "coding": [
              {
                "system": "https://fevir.net/sevco",
                "code": "STATO:0000047",
                "display": "Count"
              }
            ]
          },
          "quantity": {
            "value": 37
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG000",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
        ]
      },
      "identifier": [
        {
          "type": {
            "text": "FEvIR Linking Identifier"
          },
          "system": "https://fevir.net/FLI",
          "value": "NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG000",
          "assigner": {
            "display": "Computable Publishing LLC"
          }
        }
      ],
      "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Washout Period (3 to 14 Days)",
      "status": "active",
      "author": [
        {
          "name": "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
        }
      ],
      "useContext": [
        {
          "code": {
            "system": "https://fevir.net/resources/CodeSystem/179423",
            "code": "evidence-communication",
            "display": "Evidence Communication"
          },
          "valueCodeableConcept": {
            "coding": [
              {
                "system": "https://fevir.net/resources/CodeSystem/179423",
                "code": "ParticipantFlowEvidence",
                "display": "ParticipantFlowEvidence"
              }
            ]
          }
        }
      ],
      "variableDefinition": [
        {
          "variableRole": "population",
          "observed": {
            "reference": "#FG000",
            "type": "Group",
            "display": "Glucagon Nasal Powder/Glucagon Hydrochloride"
          }
        },
        {
          "variableRole": "outcome",
          "observed": {
            "display": "NOT COMPLETED at Washout Period (3 to 14 Days)"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "coding": [
              {
                "system": "https://fevir.net/sevco",
                "code": "STATO:0000047",
                "display": "Count"
              }
            ]
          },
          "quantity": {
            "value": 0
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG001",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
        ]
      },
      "identifier": [
        {
          "type": {
            "text": "FEvIR Linking Identifier"
          },
          "system": "https://fevir.net/FLI",
          "value": "NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG001",
          "assigner": {
            "display": "Computable Publishing LLC"
          }
        }
      ],
      "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Washout Period (3 to 14 Days)",
      "status": "active",
      "author": [
        {
          "name": "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
        }
      ],
      "useContext": [
        {
          "code": {
            "system": "https://fevir.net/resources/CodeSystem/179423",
            "code": "evidence-communication",
            "display": "Evidence Communication"
          },
          "valueCodeableConcept": {
            "coding": [
              {
                "system": "https://fevir.net/resources/CodeSystem/179423",
                "code": "ParticipantFlowEvidence",
                "display": "ParticipantFlowEvidence"
              }
            ]
          }
        }
      ],
      "variableDefinition": [
        {
          "variableRole": "population",
          "observed": {
            "reference": "#FG001",
            "type": "Group",
            "display": "Glucagon Hydrochloride Solution/Glucagon Nasal Powder"
          }
        },
        {
          "variableRole": "outcome",
          "observed": {
            "display": "NOT COMPLETED at Washout Period (3 to 14 Days)"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "coding": [
              {
                "system": "https://fevir.net/sevco",
                "code": "STATO:0000047",
                "display": "Count"
              }
            ]
          },
          "quantity": {
            "value": 0
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-flow-milestone-0-Period-2-group-FG000",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
        ]
      },
      "identifier": [
        {
          "type": {
            "text": "FEvIR Linking Identifier"
          },
          "system": "https://fevir.net/FLI",
          "value": "NCT03421379-flow-milestone-0-Period-2-group-FG000",
          "assigner": {
            "display": "Computable Publishing LLC"
          }
        }
      ],
      "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Period 2",
      "status": "active",
      "author": [
        {
          "name": "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
        }
      ],
      "useContext": [
        {
          "code": {
            "system": "https://fevir.net/resources/CodeSystem/179423",
            "code": "evidence-communication",
            "display": "Evidence Communication"
          },
          "valueCodeableConcept": {
            "coding": [
              {
                "system": "https://fevir.net/resources/CodeSystem/179423",
                "code": "ParticipantFlowEvidence",
                "display": "ParticipantFlowEvidence"
              }
            ]
          }
        }
      ],
      "variableDefinition": [
        {
          "variableRole": "population",
          "observed": {
            "reference": "#FG000",
            "type": "Group",
            "display": "Glucagon Nasal Powder/Glucagon Hydrochloride"
          }
        },
        {
          "variableRole": "outcome",
          "observed": {
            "display": "STARTED at Period 2"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "coding": [
              {
                "system": "https://fevir.net/sevco",
                "code": "STATO:0000047",
                "display": "Count"
              }
            ]
          },
          "quantity": {
            "value": 32
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-flow-milestone-0-Period-2-group-FG001",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
        ]
      },
      "identifier": [
        {
          "type": {
            "text": "FEvIR Linking Identifier"
          },
          "system": "https://fevir.net/FLI",
          "value": "NCT03421379-flow-milestone-0-Period-2-group-FG001",
          "assigner": {
            "display": "Computable Publishing LLC"
          }
        }
      ],
      "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Period 2",
      "status": "active",
      "author": [
        {
          "name": "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
        }
      ],
      "useContext": [
        {
          "code": {
            "system": "https://fevir.net/resources/CodeSystem/179423",
            "code": "evidence-communication",
            "display": "Evidence Communication"
          },
          "valueCodeableConcept": {
            "coding": [
              {
                "system": "https://fevir.net/resources/CodeSystem/179423",
                "code": "ParticipantFlowEvidence",
                "display": "ParticipantFlowEvidence"
              }
            ]
          }
        }
      ],
      "variableDefinition": [
        {
          "variableRole": "population",
          "observed": {
            "reference": "#FG001",
            "type": "Group",
            "display": "Glucagon Hydrochloride Solution/Glucagon Nasal Powder"
          }
        },
        {
          "variableRole": "outcome",
          "observed": {
            "display": "STARTED at Period 2"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "coding": [
              {
                "system": "https://fevir.net/sevco",
                "code": "STATO:0000047",
                "display": "Count"
              }
            ]
          },
          "quantity": {
            "value": 37
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-flow-milestone-1-Period-2-group-FG000",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
        ]
      },
      "identifier": [
        {
          "type": {
            "text": "FEvIR Linking Identifier"
          },
          "system": "https://fevir.net/FLI",
          "value": "NCT03421379-flow-milestone-1-Period-2-group-FG000",
          "assigner": {
            "display": "Computable Publishing LLC"
          }
        }
      ],
      "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Period 2",
      "status": "active",
      "author": [
        {
          "name": "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
        }
      ],
      "useContext": [
        {
          "code": {
            "system": "https://fevir.net/resources/CodeSystem/179423",
            "code": "evidence-communication",
            "display": "Evidence Communication"
          },
          "valueCodeableConcept": {
            "coding": [
              {
                "system": "https://fevir.net/resources/CodeSystem/179423",
                "code": "ParticipantFlowEvidence",
                "display": "ParticipantFlowEvidence"
              }
            ]
          }
        }
      ],
      "variableDefinition": [
        {
          "variableRole": "population",
          "observed": {
            "reference": "#FG000",
            "type": "Group",
            "display": "Glucagon Nasal Powder/Glucagon Hydrochloride"
          }
        },
        {
          "variableRole": "outcome",
          "observed": {
            "display": "COMPLETED at Period 2"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "coding": [
              {
                "system": "https://fevir.net/sevco",
                "code": "STATO:0000047",
                "display": "Count"
              }
            ]
          },
          "quantity": {
            "value": 32
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-flow-milestone-1-Period-2-group-FG001",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
        ]
      },
      "identifier": [
        {
          "type": {
            "text": "FEvIR Linking Identifier"
          },
          "system": "https://fevir.net/FLI",
          "value": "NCT03421379-flow-milestone-1-Period-2-group-FG001",
          "assigner": {
            "display": "Computable Publishing LLC"
          }
        }
      ],
      "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Period 2",
      "status": "active",
      "author": [
        {
          "name": "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
        }
      ],
      "useContext": [
        {
          "code": {
            "system": "https://fevir.net/resources/CodeSystem/179423",
            "code": "evidence-communication",
            "display": "Evidence Communication"
          },
          "valueCodeableConcept": {
            "coding": [
              {
                "system": "https://fevir.net/resources/CodeSystem/179423",
                "code": "ParticipantFlowEvidence",
                "display": "ParticipantFlowEvidence"
              }
            ]
          }
        }
      ],
      "variableDefinition": [
        {
          "variableRole": "population",
          "observed": {
            "reference": "#FG001",
            "type": "Group",
            "display": "Glucagon Hydrochloride Solution/Glucagon Nasal Powder"
          }
        },
        {
          "variableRole": "outcome",
          "observed": {
            "display": "COMPLETED at Period 2"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "coding": [
              {
                "system": "https://fevir.net/sevco",
                "code": "STATO:0000047",
                "display": "Count"
              }
            ]
          },
          "quantity": {
            "value": 37
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-flow-milestone-2-Period-2-group-FG000",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
        ]
      },
      "identifier": [
        {
          "type": {
            "text": "FEvIR Linking Identifier"
          },
          "system": "https://fevir.net/FLI",
          "value": "NCT03421379-flow-milestone-2-Period-2-group-FG000",
          "assigner": {
            "display": "Computable Publishing LLC"
          }
        }
      ],
      "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Period 2",
      "status": "active",
      "author": [
        {
          "name": "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
        }
      ],
      "useContext": [
        {
          "code": {
            "system": "https://fevir.net/resources/CodeSystem/179423",
            "code": "evidence-communication",
            "display": "Evidence Communication"
          },
          "valueCodeableConcept": {
            "coding": [
              {
                "system": "https://fevir.net/resources/CodeSystem/179423",
                "code": "ParticipantFlowEvidence",
                "display": "ParticipantFlowEvidence"
              }
            ]
          }
        }
      ],
      "variableDefinition": [
        {
          "variableRole": "population",
          "observed": {
            "reference": "#FG000",
            "type": "Group",
            "display": "Glucagon Nasal Powder/Glucagon Hydrochloride"
          }
        },
        {
          "variableRole": "outcome",
          "observed": {
            "display": "NOT COMPLETED at Period 2"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "coding": [
              {
                "system": "https://fevir.net/sevco",
                "code": "STATO:0000047",
                "display": "Count"
              }
            ]
          },
          "quantity": {
            "value": 0
          }
        }
      ]
    },
    {
      "resourceType": "Evidence",
      "id": "NCT03421379-flow-milestone-2-Period-2-group-FG001",
      "meta": {
        "profile": [
          "http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"
        ]
      },
      "identifier": [
        {
          "type": {
            "text": "FEvIR Linking Identifier"
          },
          "system": "https://fevir.net/FLI",
          "value": "NCT03421379-flow-milestone-2-Period-2-group-FG001",
          "assigner": {
            "display": "Computable Publishing LLC"
          }
        }
      ],
      "title": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Period 2",
      "status": "active",
      "author": [
        {
          "name": "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"
        }
      ],
      "useContext": [
        {
          "code": {
            "system": "https://fevir.net/resources/CodeSystem/179423",
            "code": "evidence-communication",
            "display": "Evidence Communication"
          },
          "valueCodeableConcept": {
            "coding": [
              {
                "system": "https://fevir.net/resources/CodeSystem/179423",
                "code": "ParticipantFlowEvidence",
                "display": "ParticipantFlowEvidence"
              }
            ]
          }
        }
      ],
      "variableDefinition": [
        {
          "variableRole": "population",
          "observed": {
            "reference": "#FG001",
            "type": "Group",
            "display": "Glucagon Hydrochloride Solution/Glucagon Nasal Powder"
          }
        },
        {
          "variableRole": "outcome",
          "observed": {
            "display": "NOT COMPLETED at Period 2"
          }
        }
      ],
      "statistic": [
        {
          "statisticType": {
            "coding": [
              {
                "system": "https://fevir.net/sevco",
                "code": "STATO:0000047",
                "display": "Count"
              }
            ]
          },
          "quantity": {
            "value": 0
          }
        }
      ]
    }
  ],
  "url": "https://fevir.net/resources/Composition/399871",
  "identifier": [
    {
      "type": {
        "coding": [
          {
            "system": "http://terminology.hl7.org/CodeSystem/v2-0203",
            "code": "ACSN",
            "display": "Accession ID"
          }
        ],
        "text": "FEvIR Object Identifier"
      },
      "system": "https://fevir.net/FOI",
      "value": "399871",
      "assigner": {
        "display": "Computable Publishing LLC"
      }
    },
    {
      "type": {
        "text": "FEvIR Linking Identifier"
      },
      "system": "https://fevir.net/FLI",
      "value": "NCT03421379-participant-flow-report",
      "assigner": {
        "display": "Computable Publishing LLC"
      }
    }
  ],
  "status": "final",
  "type": {
    "coding": [
      {
        "system": "https://fevir.net/resources/CodeSystem/179423",
        "code": "ParticipantFlowReport",
        "display": "ParticipantFlowReport"
      }
    ],
    "text": "Participant Flow Report"
  },
  "date": "2025-12-11T20:35:21.032Z",
  "author": [
    {
      "display": "[No author listed.]"
    }
  ],
  "title": "Participant Flow Report for NCT03421379",
  "custodian": {
    "reference": "Organization/118079",
    "type": "Organization",
    "display": "Computable Publishing LLC"
  },
  "relatesTo": [
    {
      "type": "cite-as",
      "targetMarkdown": "Participant Flow Report for NCT03421379 [Database Entry: FHIR Composition Resource]. Contributors: [No author listed.] [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 399871. Revised 2025-12-11. Available at: https://fevir.net/resources/Composition/399871. Computable resource at: https://fevir.net/resources/Composition/399871#json."
    }
  ],
  "section": [
    {
      "title": "Flow PreAssignment Details",
      "code": {
        "coding": [
          {
            "system": "https://fevir.net/resources/CodeSystem/179423",
            "code": "participant-flow-details",
            "display": "Participant Flow Details"
          }
        ],
        "text": "FlowPreAssignmentDetails"
      },
      "text": {
        "status": "generated",
        "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Participants were randomized to receive either nasal glucagon or intramuscular (IM) glucagon in the first period, followed by the alternate treatment in the second period.</div>"
      }
    },
    {
      "title": "Flow Group List",
      "code": {
        "text": "FlowGroupList"
      },
      "text": {
        "status": "generated",
        "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Glucagon Nasal Powder/Glucagon Hydrochloride, Glucagon Hydrochloride Solution/Glucagon Nasal Powder</div>"
      },
      "entry": [
        {
          "reference": "#FG000",
          "type": "Group",
          "display": "Glucagon Nasal Powder/Glucagon Hydrochloride"
        },
        {
          "reference": "#FG001",
          "type": "Group",
          "display": "Glucagon Hydrochloride Solution/Glucagon Nasal Powder"
        }
      ]
    },
    {
      "title": "STARTED at Period 1",
      "code": {
        "coding": [
          {
            "system": "https://fevir.net/resources/CodeSystem/179423",
            "code": "results",
            "display": "Results"
          }
        ],
        "text": "Participant Flow Results"
      },
      "focus": {
        "display": "STARTED at Period 1"
      },
      "text": {
        "status": "empty",
        "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
      },
      "entry": [
        {
          "reference": "#NCT03421379-flow-milestone-0-Period-1-group-FG000",
          "type": "Evidence",
          "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Period 1"
        },
        {
          "reference": "#NCT03421379-flow-milestone-0-Period-1-group-FG001",
          "type": "Evidence",
          "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Period 1"
        }
      ]
    },
    {
      "title": "Received at Least One Dose of Study Drug at Period 1",
      "code": {
        "coding": [
          {
            "system": "https://fevir.net/resources/CodeSystem/179423",
            "code": "results",
            "display": "Results"
          }
        ],
        "text": "Participant Flow Results"
      },
      "focus": {
        "display": "Received at Least One Dose of Study Drug at Period 1"
      },
      "text": {
        "status": "empty",
        "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
      },
      "entry": [
        {
          "reference": "#NCT03421379-flow-milestone-1-Period-1-group-FG000",
          "type": "Evidence",
          "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - Received at Least One Dose of Study Drug at Period 1"
        },
        {
          "reference": "#NCT03421379-flow-milestone-1-Period-1-group-FG001",
          "type": "Evidence",
          "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - Received at Least One Dose of Study Drug at Period 1"
        }
      ]
    },
    {
      "title": "COMPLETED at Period 1",
      "code": {
        "coding": [
          {
            "system": "https://fevir.net/resources/CodeSystem/179423",
            "code": "results",
            "display": "Results"
          }
        ],
        "text": "Participant Flow Results"
      },
      "focus": {
        "display": "COMPLETED at Period 1"
      },
      "text": {
        "status": "empty",
        "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
      },
      "entry": [
        {
          "reference": "#NCT03421379-flow-milestone-2-Period-1-group-FG000",
          "type": "Evidence",
          "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Period 1"
        },
        {
          "reference": "#NCT03421379-flow-milestone-2-Period-1-group-FG001",
          "type": "Evidence",
          "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Period 1"
        }
      ]
    },
    {
      "title": "NOT COMPLETED at Period 1",
      "code": {
        "coding": [
          {
            "system": "https://fevir.net/resources/CodeSystem/179423",
            "code": "results",
            "display": "Results"
          }
        ],
        "text": "Participant Flow Results"
      },
      "focus": {
        "display": "NOT COMPLETED at Period 1"
      },
      "text": {
        "status": "empty",
        "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
      },
      "entry": [
        {
          "reference": "#NCT03421379-flow-milestone-3-Period-1-group-FG000",
          "type": "Evidence",
          "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Period 1"
        },
        {
          "reference": "#NCT03421379-flow-milestone-3-Period-1-group-FG001",
          "type": "Evidence",
          "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Period 1"
        }
      ]
    },
    {
      "title": "Reasons for withdraw at Period 1",
      "code": {
        "coding": [
          {
            "system": "https://fevir.net/resources/CodeSystem/179423",
            "code": "results",
            "display": "Results"
          }
        ],
        "text": "Participant Flow Results"
      },
      "focus": {
        "display": "Reasons for withdraw at Period 1"
      },
      "text": {
        "status": "empty",
        "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
      },
      "entry": [
        {
          "reference": "#NCT03421379-flow-reason-Period-1-group-FG000",
          "type": "Evidence",
          "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - Reasons for withdraw at Period 1"
        },
        {
          "reference": "#NCT03421379-flow-reason-Period-1-group-FG001",
          "type": "Evidence",
          "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - Reasons for withdraw at Period 1"
        }
      ]
    },
    {
      "title": "STARTED at Washout Period (3 to 14 Days)",
      "code": {
        "coding": [
          {
            "system": "https://fevir.net/resources/CodeSystem/179423",
            "code": "results",
            "display": "Results"
          }
        ],
        "text": "Participant Flow Results"
      },
      "focus": {
        "display": "STARTED at Washout Period (3 to 14 Days)"
      },
      "text": {
        "status": "empty",
        "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
      },
      "entry": [
        {
          "reference": "#NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG000",
          "type": "Evidence",
          "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Washout Period (3 to 14 Days)"
        },
        {
          "reference": "#NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG001",
          "type": "Evidence",
          "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Washout Period (3 to 14 Days)"
        }
      ]
    },
    {
      "title": "COMPLETED at Washout Period (3 to 14 Days)",
      "code": {
        "coding": [
          {
            "system": "https://fevir.net/resources/CodeSystem/179423",
            "code": "results",
            "display": "Results"
          }
        ],
        "text": "Participant Flow Results"
      },
      "focus": {
        "display": "COMPLETED at Washout Period (3 to 14 Days)"
      },
      "text": {
        "status": "empty",
        "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
      },
      "entry": [
        {
          "reference": "#NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG000",
          "type": "Evidence",
          "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Washout Period (3 to 14 Days)"
        },
        {
          "reference": "#NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG001",
          "type": "Evidence",
          "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Washout Period (3 to 14 Days)"
        }
      ]
    },
    {
      "title": "NOT COMPLETED at Washout Period (3 to 14 Days)",
      "code": {
        "coding": [
          {
            "system": "https://fevir.net/resources/CodeSystem/179423",
            "code": "results",
            "display": "Results"
          }
        ],
        "text": "Participant Flow Results"
      },
      "focus": {
        "display": "NOT COMPLETED at Washout Period (3 to 14 Days)"
      },
      "text": {
        "status": "empty",
        "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
      },
      "entry": [
        {
          "reference": "#NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG000",
          "type": "Evidence",
          "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Washout Period (3 to 14 Days)"
        },
        {
          "reference": "#NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG001",
          "type": "Evidence",
          "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Washout Period (3 to 14 Days)"
        }
      ]
    },
    {
      "title": "STARTED at Period 2",
      "code": {
        "coding": [
          {
            "system": "https://fevir.net/resources/CodeSystem/179423",
            "code": "results",
            "display": "Results"
          }
        ],
        "text": "Participant Flow Results"
      },
      "focus": {
        "display": "STARTED at Period 2"
      },
      "text": {
        "status": "empty",
        "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
      },
      "entry": [
        {
          "reference": "#NCT03421379-flow-milestone-0-Period-2-group-FG000",
          "type": "Evidence",
          "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Period 2"
        },
        {
          "reference": "#NCT03421379-flow-milestone-0-Period-2-group-FG001",
          "type": "Evidence",
          "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Period 2"
        }
      ]
    },
    {
      "title": "COMPLETED at Period 2",
      "code": {
        "coding": [
          {
            "system": "https://fevir.net/resources/CodeSystem/179423",
            "code": "results",
            "display": "Results"
          }
        ],
        "text": "Participant Flow Results"
      },
      "focus": {
        "display": "COMPLETED at Period 2"
      },
      "text": {
        "status": "empty",
        "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
      },
      "entry": [
        {
          "reference": "#NCT03421379-flow-milestone-1-Period-2-group-FG000",
          "type": "Evidence",
          "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Period 2"
        },
        {
          "reference": "#NCT03421379-flow-milestone-1-Period-2-group-FG001",
          "type": "Evidence",
          "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Period 2"
        }
      ]
    },
    {
      "title": "NOT COMPLETED at Period 2",
      "code": {
        "coding": [
          {
            "system": "https://fevir.net/resources/CodeSystem/179423",
            "code": "results",
            "display": "Results"
          }
        ],
        "text": "Participant Flow Results"
      },
      "focus": {
        "display": "NOT COMPLETED at Period 2"
      },
      "text": {
        "status": "empty",
        "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
      },
      "entry": [
        {
          "reference": "#NCT03421379-flow-milestone-2-Period-2-group-FG000",
          "type": "Evidence",
          "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Period 2"
        },
        {
          "reference": "#NCT03421379-flow-milestone-2-Period-2-group-FG001",
          "type": "Evidence",
          "display": "ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Period 2"
        }
      ]
    }
  ]
}